Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Cash from Financing Activities for 8 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 8622.39% year-over-year to $11.7 million, compared with a TTM value of $13.4 million through Dec 2025, up 146.99%, and an annual FY2025 reading of $13.4 million, up 146.99% over the prior year.
  • Cash from Financing Activities was $11.7 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $1.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $47.0 million in Q1 2021 and bottomed at -$27.4 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $2.0 million, with a median of $296500.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 39740.68% in 2021, then crashed 8244.05% in 2023.
  • Year by year, Cash from Financing Activities stood at $230000.0 in 2021, then plummeted by 1070.43% to -$2.2 million in 2022, then crashed by 735.89% to -$18.7 million in 2023, then surged by 100.72% to $134000.0 in 2024, then surged by 8622.39% to $11.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ARCT at $11.7 million in Q4 2025, $1.2 million in Q3 2025, and -$14.7 million in Q2 2025.